RxDoctor Payments Data

Todd Hamblin

Family · Logan, UTNPI 1093092678

Payments from drug & device makers

$440in general payments, 2019–2025

Across 10 payments — averaging $44.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$100
  • Seagen Inc.$99
  • Boston Scientific$64
  • Lilly USA, LLC$44
  • Dendreon Pharmaceuticals LLC$31
  • Sanofi$24
  • plus $79 from 4 others

What the payments were for

  • Food & beverage$19745%
  • Education$24355%

General payments by program year

21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$440 in reported general payments places this provider in the 55th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$54,403
Medicare patients
329
Services billed
881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide112$2,053,788
ImbruvicaIbrutinib43$779,981
Lenalidomide40$505,156
VerzenioAbemaciclib21$309,886
PiqrayAlpelisib12$263,000
AlecensaAlectinib Hcl11$236,758
IbrancePalbociclib11$190,742
XtandiEnzalutamide12$176,289
VenclextaVenetoclax22$174,846
LonsurfTrifluridine/Tipiracil Hcl11$149,363
Abiraterone Acetate37$83,553
XareltoRivaroxaban22$17,666
EliquisApixaban19$13,230
ValacyclovirValacyclovir Hcl43$1,966
Tamoxifen Citrate69$1,947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio, Olanzapine$44$310,03933 claims
Genentech USA, Inc.Alecensa$23$236,75811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,460 family providers in Utah.

Other family in Logan

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →